Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Prim. 2015;1:15065.

Article  PubMed  Google Scholar 

Brown KGM, Solomon MJ, Mahon K, O’Shannassy S. Management of colorectal cancer. BMJ. 2019;366:l4561.

Article  PubMed  Google Scholar 

Van Cutsem E, Cervantes A, Nordlinger B, Arnold D, Group EGW. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25:iii1–9.

Article  PubMed  Google Scholar 

Arango D, Wilson AJ, Shi Q, Corner GA, Arañes MJ, Nicholas C, et al. Molecular mechanisms of action and prediction of response to oxaliplatin in colorectal cancer cells. Br J Cancer. 2004;91:1931–46.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Di Francesco AM, Ruggiero A, Riccardi R. Cellular and molecular aspects of drugs of the future: oxaliplatin. Cell Mol Life Sci. 2002;59:1914–27.

Article  PubMed Central  PubMed  Google Scholar 

Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R. FDA drug approval summaries: oxaliplatin. Oncologist. 2004;9:8–12.

Article  PubMed  Google Scholar 

Hsieh CC, Hsu SH, Lin CY, Liaw HJ, Li TW, Jiang KY, et al. CHK2 activation contributes to the development of oxaliplatin resistance in colorectal cancer. Br J Cancer. 2022;127:1615–28.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L. Role of oxaliplatin in the treatment of colorectal cancer. Ther Clin Risk Manag. 2009;5:229–38.

Article  PubMed Central  PubMed  Google Scholar 

Panczyk M. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years. World J Gastroenterol. 2014;20:9775–827.

Article  PubMed Central  PubMed  Google Scholar 

Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals. 2013;6:988–1038.

Article  PubMed Central  PubMed  Google Scholar 

Martinez-Balibrea E, Martinez-Cardus A, Gines A, Ruiz de Porras V, Moutinho C, Layos L, et al. Tumor-related molecular mechanisms of oxaliplatin resistance. Mol Cancer Ther. 2015;14:1767–76.

Article  CAS  PubMed  Google Scholar 

Xu R, Zhang Y, Li A, Ma Y, Cai W, Song L, et al. LY‑294002 enhances the chemosensitivity of liver cancer to oxaliplatin by blocking the PI3K/AKT/HIF‑1alpha pathway. Mol Med Rep. 2021;24:508.

Park SY, Chung YS, Park SY, Kim SH. Role of AMPK in regulation of oxaliplatin-resistant human colorectal cancer. Biomedicines. 2022;10:2690.

Wei W, Ma XD, Jiang GM, Shi B, Zhong W, Sun CL, et al. The AKT/GSK3-mediated slug expression contributes to oxaliplatin resistance in colorectal cancer via upregulation of ERCC1. Oncol Res. 2020;28:423–38.

Article  PubMed Central  PubMed  Google Scholar 

Yu T, An Q, Cao X-L, Yang H, Cui J, Li Z-J, et al. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway. Life Sci. 2020;260:118294.

Article  CAS  PubMed  Google Scholar 

Leelawat K, Narong S, Udomchaiprasertkul W, Leelawat S, Tungpradubkul S. Inhibition of PI3K increases oxaliplatin sensitivity in cholangiocarcinoma cells. Cancer Cell Int. 2009;9:3.

Article  PubMed Central  PubMed  Google Scholar 

Niehrs C. Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene. 2006;25:7469–81.

Article  CAS  PubMed  Google Scholar 

Glinka A, Wu W, Delius H, Monaghan AP, Blumenstock C, Niehrs C. Dickkopf-1 is a member of a new family of secreted proteins and functions in head induction. Nature. 1998;391:357–62.

Article  CAS  PubMed  Google Scholar 

Kimura H, Fumoto K, Shojima K, Nojima S, Osugi Y, Tomihara H, et al. CKAP4 is a Dickkopf1 receptor and is involved in tumor progression. J Clin Invest. 2016;126:2689–705.

Article  PubMed Central  PubMed  Google Scholar 

Mao B, Wu W, Li Y, Hoppe D, Stannek P, Glinka A, et al. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature. 2001;411:321–5.

Article  CAS  PubMed  Google Scholar 

Huang J, Lu T, Kuang W. Prognostic role of dickkopf-1 in patients with cancer. Medicine. 2020;99:e20388.

Article  PubMed Central  PubMed  Google Scholar 

Yamabuki T, Takano A, Hayama S, Ishikawa N, Kato T, Miyamoto M, et al. Dikkopf-1 as a novel serologic and prognostic biomarker for lung and esophageal carcinomas. Cancer Res. 2007;67:2517–25.

Article  CAS  PubMed  Google Scholar 

Kemik O, Kemik AS, Sumer A, Begenik H, Purisa S, Tuzun S, et al. Relationship between clinicopathologic variables and serum and tissue levels of Dickkopf-1 in patients with rectal cancer. J Invest Med. 2011;59:947.

Article  CAS  Google Scholar 

Sui Q, Zheng J, Liu D, Peng J, Ou Q, Tang J, et al. Dickkopf-related protein 1, a new biomarker for local immune status and poor prognosis among patients with colorectal liver Oligometastases: a retrospective study. BMC Cancer. 2019;19:1210.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Kagey MH, He X. Rationale for targeting the Wnt signalling modulator Dickkopf-1 for oncology. Br J Pharm. 2017;174:4637–50.

Article  CAS  Google Scholar 

Chen L, Li M, Li Q, Wang C-J, Xie S-Q. DKK1 promotes hepatocellular carcinoma cell migration and invasion through β-catenin/MMP7 signaling pathway. Mol Cancer. 2013;12:157.

Article  PubMed Central  PubMed  Google Scholar 

Iguchi K, Sada R, Matsumoto S, Kimura H, Zen Y, Akita M, et al. DKK1-CKAP4 signal axis promotes hepatocellular carcinoma aggressiveness. Cancer Sci. 2023;114:2063–77.

Article  CAS  PubMed Central  PubMed  Google Scholar 

Shinno N, Kimura H, Sada R, Takiguchi S, Mori M, Fumoto K, et al. Activation of the Dickkopf1-CKAP4 pathway is associated with poor prognosis of esophageal cancer and anti-CKAP4 antibody may be a new therapeutic drug. Oncogene. 2018;37:3471–84.

Article  CAS  PubMed  Google Scholar 

Akl MR, Nagpal P, Ayoub NM, Tai B, Prabhu SA, Capac CM, et al. Molecular and clinical significance of fibroblast growth factor 2 (FGF2 /bFGF) in malignancies of solid and hematological cancers for personalized therapies. Oncotarget. 2016;7:44735–62.

Article  PubMed Central  PubMed  Google Scholar 

Kikuchi A, Fumoto K, Kimura H. The Dickkopf1-cytoskeleton-associated protein 4 axis creates a novel signalling pathway and may represent a molecular target for cancer therapy. Br J Pharm. 2017;174:4651–65.

Article  CAS  Google Scholar 

Kikuchi A, Matsumoto S, Sada R. Dickkopf signaling, beyond Wnt-mediated biology. Semin Cell Dev Biol. 2022;125:55–65.

Article  CAS  PubMed  Google Scholar 

Bhavanasi D, Speer KF, Klein PS. CKAP4 is identified as a receptor for Dickkopf in cancer cells. J Clin Invest. 2016;126:2419–21.

Article  PubMed Central  PubMed  Google Scholar 

Fedi P, Bafico A, Nieto Soria A, Burgess WH, Miki T, Bottaro DP, et al. Isolation and biochemical characterization of the human Dkk-1 homologue, a novel inhibitor of mammalian Wnt signaling. J Biol Chem. 1999;274:19465–72.

Article  CAS  PubMed